Epidemiol Infect. May 2007; 135(4): 610–621. . Please click on the website link and download the pdf-file. Open Access
Handout presentations in PDF for illustrating lectures
Accessed May 2014
A Global Campaign Against Epilepsy Demonstration Project
Le syndrome respiratoire aigu provoqué par le coronavirus-2 (SARS-CoV-2), initialement décrit en Chine, est responsable
de la pandémie que nous connaissons actuellement sous le nom de coronavirus disease 2019 ou COVID-19. L'épidémie de
coronavirus a été déclarée « urgence de santé publi...que mondiale » par l'Organisation mondiale de la santé (OMS) le 30 janvier 2020 . L'Afrique a été atteinte plus tard que les autres continents, mais à la date du 3 mai, tous les pays africains
avaient notifié au moins un cas. À la date du 09 juin 2020, l'Afrique comptait près de 200 000 cas confirmés, plus de
5000 décès, avec 25 pays ayant plus de 1000 cas actifs. Les patients atteints par ce virus peuvent développer des symptômes allant jusqu'à l'insuffisance respiratoire aiguë sévère
more
Key facts about major deadly diseases.This manual provides concise and up-to-date knowledge on 15 infectious diseases that have the potential to become international threats, and tips on how to respond to each of them.
You can download an interactive version directly at the website
http://www.who....int/emergencies/diseases/managing-epidemics/en/
more
Handout presentations in PDF for illustrating lectures
Accessed May 2014
The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients wit...h DM have a worse prognosis than those without DM. Diabetes can cause myocardial ischemia via micro- and macrovasculopathy and can directly exert deleterious effects on the myocardium. Hyperglycemia, hyperinsulinemia, and insulin resistance can cause alterations in vascular homeostasis. Then, reduced nitric oxide and increased reactive oxygen species levels favor inflammation leading to atherothrombotic progression and myocardial dysfunction. The classification, diagnosis, and treatment of HF for a patient with and without DM remain the same. Until now, drugs targeting neurohumoral and metabolic pathways improved mortality and morbidity in HF with reduced ejection fraction (HFrEF). Therefore, all HFrEF patients should receive guideline-directed medical therapy. By contrast, drugs modulating neurohumoral activity did not improve survival in HF with preserved ejection fraction (HFpEF) patients. Trials investigating whether sodium-glucose cotransporter-2 inhibitors are effective in HFpEF are on-going. This review will summarize the epidemiology, pathophysiology, and treatment of HF in diabetes.
more
BMC Medicine201210:107
https://doi.org/10.1186/1741-7015-10-107© Katchanov and Birbeck; licensee BioMed Central Ltd. 2012
Received: 10 July 2012Accepted: 24 September 2012Published: 24 September 2012
In 2011, the World Health Organization’s (WHO) mental health Gap Action Programme (mhGAP) r...eleased evidence-based epilepsy-care guidelines for use in low and middle income countries (LAMICs). From a
geographical, sociocultural, and political perspective, LAMICs represent a heterogenous group with significant differences in the epidemiology, etiology, and perceptions of epilepsy. Successful implementation of
the guidelines requires local adaptation for use within individual countries. For effective implementation and sustainability, the sense of ownership and empowerment must be transferred from the global health authorities to the local people. Sociocultural and financial barriers that impede the implementation of the guidelines should be
identified and ameliorated. Impact assessment and program revisions should be planned and a budget allocated to them. If effectively implemented, as intended, at the primary-care level, the mhGAP
guidelines have the potential to facilitate a substantial reduction in the epilepsy treatment gap and improve the quality of epilepsy care in resource-limited settings.
more
Global Campaign Against Epilepsy
Open AccessPublished:March 28, 2019DOI:https://doi.org/10.1016/S1473-3099(18)30730-8
The Lancet Infectious Diseases
Lancet 2012; 380: 1193–1201
Series: Epilepsy 2
If you have Tuberculosis, what is your risk from COVID-19? How can you keep yourself safe during the pandemic? Why is it important that the world does not take its eyes off TB during the Pandemic? Dr Tereza Kasaeva explains in Science in 5 this week.
Follow up to the Maseru Declaration. ZIMBABWE COUNTRY REPORT
Reporting Period: January 2013 - December 2013